62nd ASH Annual Meeting and Exposition: 332. Anticoagulation and Antithrombotic Therapy: COVID-19, Obesity and Hemorrhagic Complications

Oral and Poster Abstracts
Oral

Adult, anticoagulant drugs, Biological, Bleeding Disorders, Coronaviruses, SARS-CoV-2/COVID-19, Bleeding and Clotting, Diseases, Hemostasis, Non-Biological, Elderly, Therapies, Thrombosis, Young Adult, Study Population, Thromboembolism, Clinically relevant, Quality Improvement , Thrombotic Disorders

Moderators:

Damon E. Houghton, MD, MS, Mayo Clinic and Manila Gaddh, MD, Winship Cancer Institute of Emory University

Disclosures:

No relevant conflicts of interest to declare.

9:00 AM

576

Australian and New Zealand Registry of Anticoagulation in the Obese: Prescribing Patterns, Drug Levels and Patient Outcomes

Georgia J McCaughan, BMedSc MBBS MMed (Clin Epi)^1,2, Helen Jane Crowther, MBBS FRACP FRCPA PhD^3,4^*, Vivien Chen, PhD MBBS^5,6, Sanjeev D Chunilal, MBChB FRACP FRCPA⁷^*, Eileen Merriman, MBChB BMLSc FRACP FRCPA PhD⁸^*, Hadley Bortz, BPharm, GradCert PharmPrac, MClinPharm, MSHP⁹^*, Laura Young, MB ChB FRCPA FRACP¹⁰^*, Huyen A Tran, MBBS MSc FRACP FRCPA¹¹^*, Hiu Lam Agnes Yuen, MBBS⁷ and Jennifer Curnow, MBBS FRACP FRCPA PhD^1,4^*

¹Department of Haematology, Westmead Hospital, Western Sydney Local Health District, Sydney, Australia
²Faculty of Medicine and Health, University of Sydney, Sydney, Australia
³Department of Haematology, Blacktown Hospital, Western Sydney Local Health District, Sydney, Australia
⁴Sydney Centres for Thrombosis and Haemostasis, Sydney, Australia
⁵Department of Haematology, Concord Repatriation General Hospital, Sydney, NSW, Australia
⁶ANZAC Research Institute, University of Sydney, Sydney, NSW, Australia
⁷Monash Medical Centre, Melbourne, Australia
⁸Department of Haematology, Waitemata District Health Board, Auckland, New Zealand
⁹Department of Pharmacy, The Alfred Hospital, Melbourne, Australia
¹⁰Auckland District Health Board, Auckland, New Zealand
¹¹Department of Haematology, Alfred Hospital, Melbourne, Australia

9:15 AM

577

Increasing Doses of Anticoagulation Are Associated with Improved Survival in Hospitalized COVID-19 Patients

Filip Ionescu, MD¹^*, Girish B Nair, MD, MS, FACP²^*, Ioana Petrescu, MD¹^*, Anish S Konde, MD³^*, Markie Sue Zimmer, MD⁴, Nwabundo Anusim, MBBS⁵, Vishal Jindal, MD⁶^*, Susanna Gaikazian, MD⁶, Joseph Anderson, MD⁷^*, Michael Stender, MD⁸, Marianne Terese Huben, DO⁹^* and Ishmael Jaiyesimi, DO, MS⁶

¹Internal Medicine, William Beaumont Hospital, Royal Oak, MI
²Pulmonary and Critical Care Medicine, William Beaumont Hospital, Royal Oak, MI
³Department of Hematology and Oncology, Oakland University/William Beaumont School of Medicine, Royal Oak, MI
⁴Oakland University / William Beaumont Hospital, Royal Oak, MI
⁵Oakland University / William Beaumont Hospital, Troy, MI
⁶William Beaumont Hospital, Royal Oak, MI
⁷Oakland University/William Beaumont School of Medicine, Royal Oak
⁸Hematology Oncology, Oakland University, William Beaumont Hospital, Royal Oak, MI
⁹Oakland University/William Beaumont School of Medicine, Royal Oak, MI

9:30 AM

578

Filter Clotting with Continuous Renal Replacement Therapy in COVID-19

Rachel P. Rosovsky, MD, MPH¹, Paul Endres²^*, Soophia H Zhao³^*, Scott Krinsky³^*, Shananssa G Percy³^*, Omer Kamal⁴^*, Russel J. Roberts, PharmD, BCCCP, FCCM⁵^*, Natasha Lopez³^*, Meghan E Sise³^*, David J Steele³^*, Andrew L Lundquist³^*, Eugene P Rhee³^*, Kathryn A Hibbert³^*, Charles C Hardin³^*, Finnian R McCausland⁴^*, Peter G. Czarnecki, MD⁶^*, Walter P Mutter⁷^*, Nina E Tolkoff-Rubin³^* and Andrew S Allegretti³^*

¹Division of Hematology & Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA
²Department of Nephrology, Massachusetts General Hospital, Boston, MA
³Massachusetts General Hospital, Boston
⁴Brigham and Women’s Hospital, Boston
⁵Department of Pharmacy, Massachusetts General Hospital, Boston, MA
⁶Department of Medicine, Brigham and Women's Hospital, Boston, MA
⁷Newton Wellesley Hospital, Newton, MA

9:45 AM

579

Admission Rothman Index, Aspirin, and Intermediate Dose Anticoagulation Effects on Outcomes in COVID-19: A Multi-Site Propensity Matched Analysis

George Goshua, MD¹, Yiwen Liu²^*, Matthew L. Meizlish, MSc³^*, Rebecca Fine, MD⁴^*, Kejal Amin, PharmD⁵^*, Eric Chang, MD⁶^*, Yuxin Liu, MD⁷^*, Dayna McManus, PharmD⁸^*, Adina Petrosan, PharmD⁹^*, Cassius Ilya Ochoa Chaar, MD¹⁰^*, Hyung J. Chun, MD¹¹^*, Nicholas A. Defilippo, PharmD¹²^*, Donna S. Neuberg, ScD², Alexander B Pine, MD, PhD¹³, Kent A. Owusu, PharmD¹⁴^* and Alfred Ian Lee, MD, PhD¹⁵

¹Section of Hematology, Yale University School of Medicine, New Haven, CT
²Department of Data Science, Dana-Farber Cancer Institute, Boston, MA
³Yale University School of Medicine, New Haven
⁴Department of Internal Medicine, Yale University School of Medicine, New Haven
⁵Department of Pharmacy, Yale-New Haven Hospital, New Haven
⁶Section of Hematology, Yale University School of Medicine, New Haven
⁷Yale University, New Haven, CT
⁸Department of Pharmacy, Yale University School of Medicine, New Havem
⁹Department of Pharmacy, Yale New Haven Hospital, New Haven
¹⁰Yale School of Medicine, New Haven, CT
¹¹Department of Medicine, Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, CT
¹²University of Connecticut, Storrs
¹³Department of Medicine, Section of Hematology, Yale School of Medicine, New Haven, CT
¹⁴Yale New Haven Hospital, New Haven, CT
¹⁵Section of Hematology, Department of Internal Medicine, Yale University School of Medicine and Yale Cancer Center, New Haven, CT

10:00 AM

580

Mortality Rate and Functional Outcomes Among Patients Presenting with Anticoagulation- Associated Intracranial Hemorrhage

Sujitha Srinathan¹, Christopher Cipkar, MD, BSc²^*, Philip Chiang, MD, BMSc² and Lana A Castellucci, MD, MSc³

¹University of Ottawa, Markham, ON, Canada
²University of Ottawa, Ottawa, ON, Canada
³Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada

10:15 AM

581

Thrombosis, Bleeding, and the Effect of Anticoagulation on Survival in Critically Ill Patients with COVID-19 in the United States

Hanny Al-Samkari, MD^1,2, Shruti Gupta, MD^1,3^*, Rebecca Karp Leaf, MD^1,2^*, Wei Wang, PhD⁴^*, Rachel P. Rosovsky, MD, MPH^1,2, Kenneth A. Bauer, MD^1,5 and David E. Leaf, MD, MMSc^1,3^*

¹Harvard Medical School, Boston, MA
²Division of Hematology, Massachusetts General Hospital, Boston, MA
³Division of Renal Medicine, Brigham and Women's Hospital, Boston, MA
⁴Brigham and Women's Hospital, Boston, MA
⁵Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, MA

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

332.O2.6 332. Anticoagulation and Antithrombotic Therapy: COVID-19, Obesity and Hemorrhagic Complications